FRANKREICH

Sartorius Stedim Biotech SA: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Retrieved on: 
Vendredi, février 16, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The person making the disclosure is a closely associated person mentioned of article 3.26) of Regulation (EU) No 596/2014 of April 16, 2014 on market abuse.
  • Please give the identity and functions of the person with whom the reporting person has close personal ties.
  • Position / status: Sartorius AG legal entity related to JOACHIM KREUZBURG, CHAIRMAN OF THE BOARD and RENE FABER, CEO
    This notification is an initial notification.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Vendredi, février 16, 2024

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Vendredi, février 16, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

AMUNDI ETF – Important Information – Mergers on Amundi Funds – 09/02/2024

Retrieved on: 
Jeudi, février 15, 2024

They can also be found on Amundi website: Important information: Merger of several ETFs | Amundi ETF Luxembourg | Retail

Key Points: 
  • They can also be found on Amundi website: Important information: Merger of several ETFs | Amundi ETF Luxembourg | Retail
    The Absorbed ETFs below will merge into the Receiving ETFs on 09/02/2024.
  • The receiving tickers in green will be transferred and activated on the merger date, please find the details in the table below.
  • Tickers in green = new tickers, tickers in red = discontinued tickers.
  • Please refer to the Overview section of the Excel file attached for more information.

MyHotelMatch: Stefan Radstrom resigns from the Board of Directors

Retrieved on: 
Mercredi, février 14, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Paris, February 14, 2024 - MYHOTELMATCH, the French company that brings together luxury hoteliers on a single platform, announces the resignation of its director Stefan Radstrom.
  • On February 13, 2024, Stefan Radstrom resigned from his position as Director of MYHOTELMATCH, effective immediately.
  • The Board unanimously thanked Stefan Radstrom for his service to the Company, of which he has been a director since April 8, 2022.

ROCTOOL: Reserved Capital increase of 2M€ in favor of the ENRX GROUP

Retrieved on: 
Mardi, février 13, 2024

Roctool (Euronext Growth - FR0010523167 - ALROC), specialists in mold heating and cooling technologies for plastics and composites, announced today that the ENRX Group has become a shareholder.

Key Points: 
  • Roctool (Euronext Growth - FR0010523167 - ALROC), specialists in mold heating and cooling technologies for plastics and composites, announced today that the ENRX Group has become a shareholder.
  • The Company's Board of Directors decided to issue 1,111,111 new shares to the ENRX Group at a unit price of 1.80€ (of which 0.20€ par value and 1.60€ issue premium), representing a capital increase of 2€ million.
  • As part of the transaction, ENRX Group will join the Company's Board of Directors.
  • For information, a shareholder holding 1% of the capital before the transaction will hold 0.80% after the transaction (non-diluted basis).

Linedata Services: Full-year 2023 results Revenue growth: +6.1% EBITDA margin: 29.1% of revenue

Retrieved on: 
Mardi, février 13, 2024

As a result of the fall of the main currencies against the euro in 2023, the increase in reported terms is limited to 3.9%.

Key Points: 
  • As a result of the fall of the main currencies against the euro in 2023, the increase in reported terms is limited to 3.9%.
  • Excluding exchange rate effects and the acquisition of Audaxys, revenue was up 6.4%, and the EBITDA margin was stable compared with the previous year at 34.7%.
  • The EBITDA margin came in at 29.1% of revenue, virtually unchanged from the previous year.
  • Net debt* stood at €75.4m, or 1.5x consolidated EBITDA 2023 excluding the impact of IFRS 16.

BROADPEAK SA: Broadpeak reports annual revenue

Retrieved on: 
Mardi, février 13, 2024

At 31 December, annual revenue amounted to €39m, compared with €41.9m in 2022, for a decrease of 6.8%.

Key Points: 
  • At 31 December, annual revenue amounted to €39m, compared with €41.9m in 2022, for a decrease of 6.8%.
  • This disappointing trend reflects tighter business conditions, with a marked wait-and-see attitude on the part of TV and telecom operators (accounting for over 80% of Broadpeak revenue).
  • The region ultimately posted an increase of 23.6%, for revenue of €4.7m, now accounting for 12% of the Group’s total business activity.
  • an increase in the contribution of recurring revenue, solid and sustainable growth, and a sharp increase in margins.

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Retrieved on: 
Mardi, février 13, 2024

“We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Key Points: 
  • “We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • We look forward to scientific exchange with the IBD community at ECCO,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.
  • The Symposium will be broadcasted live and is accessible publicly here .

Guerbet: 2023 revenue

Retrieved on: 
Jeudi, février 8, 2024

The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.

Key Points: 
  • The Diagnostic Imaging division posted revenue growth of 6.3 % at CER in 2023.
  • X-ray sales grew 7% in 2023 at CER, thanks to the robust sales trend of Xenetix®, which offset the decline in Optiray®revenues; this trend reversed in the fourth quarter of 2023, a period marked by growth for the entire X-ray division of 12.5% at CER.
  • For the 2023 financial year, after meeting its sales growth target, Guerbet will achieve a restated EBITDA margin rate3 higher than the 11% expected.
  • This objective is now largely supported by the favourable change in the product mix as well as cost control observed in the fourth quarter of 2023.